Print Page  |  Close Window

2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle Download Print
08/14/17BrainStorm Announces Second Quarter 2017 Financial ResultsDownload PDFPrinter Friendly Version
08/10/17Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16Download PDFPrinter Friendly Version
08/07/17BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government AffairsDownload PDFPrinter Friendly Version
07/25/17BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALSDownload PDFPrinter Friendly Version
07/21/17Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALSDownload PDFPrinter Friendly Version
07/18/17BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALSDownload PDFPrinter Friendly Version
07/03/17Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALSDownload PDFPrinter Friendly Version
06/14/17BrainStorm to Provide Corporate Update at the BIO International ConventionDownload PDFPrinter Friendly Version
06/13/17BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation AuthorityDownload PDFPrinter Friendly Version
05/22/17BrainStorm to Present at Cell & Gene Exchange Conference in Washington DCDownload PDFPrinter Friendly Version
05/16/17BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS StudyDownload PDFPrinter Friendly Version
05/15/17BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate UpdateDownload PDFPrinter Friendly Version
05/01/17BrainStorm to Present at Two Scientific Conferences in MayDownload PDFPrinter Friendly Version
04/20/17Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in BostonDownload PDFPrinter Friendly Version
04/19/17BrainStorm Announces Publication of NurOwn® Autism Research StudyDownload PDFPrinter Friendly Version
03/30/17BrainStorm Announces Financial Results for 2016 and Provides Business UpdateDownload PDFPrinter Friendly Version
03/22/17BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment ForumDownload PDFPrinter Friendly Version
03/06/17BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical OfficerDownload PDFPrinter Friendly Version
03/01/17BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption ProductDownload PDFPrinter Friendly Version
02/27/17BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial SuccessDownload PDFPrinter Friendly Version
02/21/17BrainStorm Seeking Approval To Distribute NurOwn® in CanadaDownload PDFPrinter Friendly Version
02/16/17City of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical TrialDownload PDFPrinter Friendly Version
02/06/17BrainStorm CEO to Present at the BIO CEO & Investor ConferenceDownload PDFPrinter Friendly Version
01/30/17BrainStorm Announces Validation of NurOwn® Cryopreservation ProcessDownload PDFPrinter Friendly Version
01/17/17BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in MiamiDownload PDFPrinter Friendly Version
01/05/17BrainStorm CEO to Present at the 9th Annual Biotech ShowcaseDownload PDFPrinter Friendly Version